Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation

US9850463B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9850463-B2
Application numberUS-201313756489-A
CountryUS
Kind codeB2
Filing dateJan 31, 2013
Priority dateFeb 1, 2012
Publication dateDec 26, 2017
Grant dateDec 26, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The production of high quality retinal pigmented epithelium (RPE) cells is necessary for research and potential therapeutic uses. Especially desirable are methods for the production of RPE cells using xeno-free culture conditions. Disclosed herein are novel methods for the production of RPE cells from pluripotent cells with high yields, including xeno-free production methods. Also provided are methods of efficiently isolating RPE cells from cultures containing heterogeneous cell types, allowing for substantially pure RPE cell cultures to be established. Additionally, novel methods for the cryopreservation of RPE cells are provided.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of producing RPE cells from pluripotent cells under xeno-free culture conditions, comprising (a) culturing pluripotent cells on a first non-cellular xeno-free substrate in a xeno-free growth medium supplemented with one or more compositions which substantially maintains pluripotent cells in a pluripotent state, wherein the pluripotent cells are embryonic stem cells or induced pluripotent stem cells; (b) replacing the growth medium with a xeno-free growth medium lacking any composition which maintains cells in a pluripotent state, wherein the cultured cells have not reached confluence are not overgrown at the time of such replacement of growth medium; (c) allowing the cultured cells on the first non-cellular xeno-free substrate to undergo spontaneous differentiation, which results in some of the pluripotent cells differentiating into RPE cells; (d) physically separating the RPE cells from the first non-cellular xeno-free substrate; and (e) culturing the isolated RPE cells on a second non-cellular xeno-free substrate in xeno-free growth medium. 2. The method of claim 1 , wherein the pluripotent cells are human cells. 3. The method of claim 1 wherein, the first non-cellular xeno-free substrate is selected from the group consisting of human or recombinant vitronectin, laminin, poly-lysine-D, acrylate functionalized with peptides, parylene membrane coated with human or recombinant vitronectin, parylene membrane coated with laminin, and parylene membrane coated with human or recombinant fibronectin. 4. The method of claim 1 wherein the xeno-free growth medium is MX-302 medium or E8 medium. 5. The method of claim 1 wherein the one or more compositions which substantially maintains pluripotent cells in a pluripotent state is basic fibroblast growth factor. 6. The method of claim 5 , wherein basic fibroblast growth factor is present in the growth medium at a concentration between 50 and 100 ug/ml. 7. The method of claim 1 wherein the one or more compositions which substantially maintains pluripotent cells in a pluripotent state is transforming growth factor Beta-1. 8. The method of claim 7 wherein the transforming growth factor Beta-1 is present in the growth medium at a concentration of 0.1 ng/ml to 1 ng/ml. 9. The method of claim 3 , wherein the selected xeno-free substrate is human or recombinant vitronectin. 10. The method of claim 3 , wherein the selected xeno-free substrate is parylene membrane coated with human or recombinant vitronectin.

Assignees

Inventors

Classifications

  • Xeno-free medium and culture conditions · CPC title

  • from embryonic cells · CPC title

  • C12N5/0621Primary

    Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062) · CPC title

  • Transforming growth factor beta (TGF-β) · CPC title

  • Basic fibroblast growth factor (bFGF, FGF-2) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9850463B2 cover?
The production of high quality retinal pigmented epithelium (RPE) cells is necessary for research and potential therapeutic uses. Especially desirable are methods for the production of RPE cells using xeno-free culture conditions. Disclosed herein are novel methods for the production of RPE cells from pluripotent cells with high yields, including xeno-free production methods. Also provided are …
Who is the assignee on this patent?
Univ California, Univ Southern California
What technology area does this patent fall under?
Primary CPC classification C12N5/0621. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).